Free Biopharma Daily Stock Updates - 05/06/21

$XBI $126 -2%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$BNTX -2% & $PFE -2% to provide covid vaccine doses to Olympic athletes. source

$MRNA -1% supply agreement with Switzerland for 7 million booster vaccine doses. source

Pipeline Updates

$CRSP -5% & $NKTX +18% development collaboration. source

$CORT +2% Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH). source

$TARS 0% Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis. source

$CORT +2% Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer. source

$FUSN -1% Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R. source

$CYTK -1% Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM. source

$AGTC -4% Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial. source

Financial Updates

$QURE +8% Closes licensing agreement with CSL Behring for exclusive global rights to etranacogene dezaparvovec. source

$SWTX +5% in-licensed portfolio of small molecule inhibitors of the TEA Domain (TEAD). source